[{"orgOrder":0,"company":"Aadi Bioscience","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Razuprotafib","moa":"Receptor-type tyrosine-protein phosphatase beta","graph1":"Ophthalmology","graph2":"Phase I","graph3":"Aadi Bioscience","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Aadi Bioscience \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Aadi Bioscience \/ Inapplicable"},{"orgOrder":0,"company":"Benobio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"SOUTH KOREA","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"BBC1501","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Phase I","graph3":"Benobio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Benobio \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Benobio \/ Inapplicable"},{"orgOrder":0,"company":"EyeD Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"BELGIUM","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Timolol Maleate","moa":"Beta-2 adrenergic receptor | Beta-1 adrenergic receptor","graph1":"Ophthalmology","graph2":"Phase I","graph3":"EyeD Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Implant","sponsorNew":"EyeD Pharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"EyeD Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Laboratorios Sophia","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"MEXICO","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"PRO-229","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Phase I","graph3":"Laboratorios Sophia","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Laboratorios Sophia \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Laboratorios Sophia \/ Inapplicable"},{"orgOrder":0,"company":"Laboratorios Sophia","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"MEXICO","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"PRO-240","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Phase I","graph3":"Laboratorios Sophia","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Laboratorios Sophia \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Laboratorios Sophia \/ Inapplicable"},{"orgOrder":0,"company":"Laboratorios Sophia","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"MEXICO","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"PRO-190","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Phase I","graph3":"Laboratorios Sophia","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Laboratorios Sophia \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Laboratorios Sophia \/ Inapplicable"},{"orgOrder":0,"company":"Asociaci\u00f3n para Evitar la Ceguera en M\u00e9xico","sponsor":"Emmecell","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"EO2002","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Phase I","graph3":"Asociaci\u00f3n para Evitar la Ceguera en M\u00e9xico","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intracameral Injection","sponsorNew":"Asociaci\u00f3n para Evitar la Ceguera en M\u00e9xico \/ Emmecell","highestDevelopmentStatusID":"6","companyTruncated":"Asociaci\u00f3n para Evitar la Ceguera en M\u00e9xico \/ Emmecell"},{"orgOrder":0,"company":"Asociaci\u00f3n para Evitar la Ceguera en M\u00e9xico","sponsor":"Emmecell","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"EO2002","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Phase I","graph3":"Asociaci\u00f3n para Evitar la Ceguera en M\u00e9xico","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intracameral Injection","sponsorNew":"Asociaci\u00f3n para Evitar la Ceguera en M\u00e9xico \/ Emmecell","highestDevelopmentStatusID":"6","companyTruncated":"Asociaci\u00f3n para Evitar la Ceguera en M\u00e9xico \/ Emmecell"},{"orgOrder":0,"company":"Ocular Therapeutix","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"HPAPI","year":"2021","type":"Inapplicable","leadProduct":"Travoprost","moa":"Prostanoid FP receptor","graph1":"Ophthalmology","graph2":"Phase I","graph3":"Ocular Therapeutix","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intracameral Implant","sponsorNew":"Ocular Therapeutix \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Ocular Therapeutix \/ Inapplicable"},{"orgOrder":0,"company":"Frontera Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"FT-003","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Phase I","graph3":"Frontera Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intraocular Injection","sponsorNew":"Frontera Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Frontera Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Chengdu Origen Biotechnology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"KH631","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Phase I","graph3":"Chengdu Origen Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intraocular Injection","sponsorNew":"Chengdu Origen Biotechnology \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Chengdu Origen Biotechnology \/ Inapplicable"},{"orgOrder":0,"company":"PharmAbcine","sponsor":"C&R Research","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"SOUTH KOREA","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"PMC-403","moa":"Tie2","graph1":"Ophthalmology","graph2":"Phase I","graph3":"PharmAbcine","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal","sponsorNew":"PharmAbcine \/ C&R Research","highestDevelopmentStatusID":"6","companyTruncated":"PharmAbcine \/ C&R Research"},{"orgOrder":0,"company":"PharmAbcine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"SOUTH KOREA","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"PMC-403","moa":"Tie2","graph1":"Ophthalmology","graph2":"Phase I","graph3":"PharmAbcine","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal","sponsorNew":"PharmAbcine \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"PharmAbcine \/ Inapplicable"},{"orgOrder":0,"company":"PharmAbcine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"SOUTH KOREA","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"PMC-403","moa":"Tie2","graph1":"Ophthalmology","graph2":"Phase I","graph3":"PharmAbcine","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal","sponsorNew":"PharmAbcine \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"PharmAbcine \/ Inapplicable"},{"orgOrder":0,"company":"4D Molecular Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"4D-110","moa":"REP1","graph1":"Ophthalmology","graph2":"Phase I","graph3":"4D Molecular Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"4D Molecular Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"4D Molecular Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"4D Molecular Therapeutics","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"4D-110","moa":"REP1","graph1":"Ophthalmology","graph2":"Phase I","graph3":"4D Molecular Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"4D Molecular Therapeutics \/ F. Hoffmann-La Roche","highestDevelopmentStatusID":"6","companyTruncated":"4D Molecular Therapeutics \/ F. Hoffmann-La Roche"},{"orgOrder":0,"company":"4D Molecular Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"4D-110","moa":"REP1","graph1":"Ophthalmology","graph2":"Phase I","graph3":"4D Molecular Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"4D Molecular Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"4D Molecular Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"AiViva Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"AIV007","moa":"VEGF receptor","graph1":"Ophthalmology","graph2":"Phase I","graph3":"AiViva Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"AiViva Biopharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"AiViva Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"AiViva Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"AIV007","moa":"VEGF receptor","graph1":"Ophthalmology","graph2":"Phase I","graph3":"AiViva Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"AiViva Biopharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"AiViva Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"AskGene Pharma Inc","sponsor":"Aosaikang Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"ASKG712","moa":"VEGF receptor","graph1":"Ophthalmology","graph2":"Phase I","graph3":"AskGene Pharma Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"AskGene Pharma Inc \/ Aosaikang Pharmaceutical","highestDevelopmentStatusID":"6","companyTruncated":"AskGene Pharma Inc \/ Aosaikang Pharmaceutical"},{"orgOrder":0,"company":"Innovent Biologics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"CHINA","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"IBI333","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Phase I","graph3":"Innovent Biologics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Innovent Biologics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Innovent Biologics \/ Inapplicable"},{"orgOrder":0,"company":"AskGene Pharma Inc","sponsor":"Aosaikang Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"ASKG712","moa":"VEGF receptor","graph1":"Ophthalmology","graph2":"Phase I","graph3":"AskGene Pharma Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"AskGene Pharma Inc \/ Aosaikang Pharmaceutical","highestDevelopmentStatusID":"6","companyTruncated":"AskGene Pharma Inc \/ Aosaikang Pharmaceutical"},{"orgOrder":0,"company":"Innovent Biologics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"CHINA","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"IBI333","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Phase I","graph3":"Innovent Biologics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Innovent Biologics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Innovent Biologics \/ Inapplicable"},{"orgOrder":0,"company":"PharmAbcine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"SOUTH KOREA","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"PMC-403","moa":"Tie2","graph1":"Ophthalmology","graph2":"Phase I","graph3":"PharmAbcine","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"PharmAbcine \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"PharmAbcine \/ Inapplicable"},{"orgOrder":0,"company":"Innovent Biologics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"CHINA","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"IBI324","moa":"VEGF-A\/Ang-2 receptor","graph1":"Ophthalmology","graph2":"Phase I","graph3":"Innovent Biologics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Innovent Biologics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Innovent Biologics \/ Inapplicable"},{"orgOrder":0,"company":"Wang Min","sponsor":"Lanyue Biotech","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"SKG0106","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Phase I","graph3":"Wang Min","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Wang Min \/ Lanyue Biotech","highestDevelopmentStatusID":"6","companyTruncated":"Wang Min \/ Lanyue Biotech"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"4D Molecular Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"SWITZERLAND","productType":"Cell and Gene therapy","year":"2021","type":"Termination","leadProduct":"4D-110","moa":"REP1","graph1":"Ophthalmology","graph2":"Phase I","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"F. Hoffmann-La Roche \/ 4D Molecular Therapeutics","highestDevelopmentStatusID":"6","companyTruncated":"F. Hoffmann-La Roche \/ 4D Molecular Therapeutics"},{"orgOrder":0,"company":"National Institutes of Health","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"scAAV2-P1ND4v2","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Phase I","graph3":"National Institutes of Health","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"National Institutes of Health \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"National Institutes of Health \/ Inapplicable"},{"orgOrder":0,"company":"OliX Pharmaceutical","sponsor":"Trial Runners, LLC","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"SOUTH KOREA","productType":"Oligonucleotide","year":"2022","type":"Inapplicable","leadProduct":"OLX10212","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Phase I","graph3":"OliX Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Solution","sponsorNew":"OliX Pharmaceutical \/ Trial Runners, LLC","highestDevelopmentStatusID":"6","companyTruncated":"OliX Pharmaceutical \/ Trial Runners, LLC"},{"orgOrder":0,"company":"OliX Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"SOUTH KOREA","productType":"Oligonucleotide","year":"2023","type":"Inapplicable","leadProduct":"OLX10212","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Phase I","graph3":"OliX Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"OliX Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"OliX Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"CDR Life","sponsor":"Boehringer Ingelheim GmbH","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"SWITZERLAND","productType":"Other Large Molecule","year":"2023","type":"Inapplicable","leadProduct":"BI 771716","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Phase I","graph3":"CDR Life","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"CDR Life \/ Boehringer Ingelheim GmbH","highestDevelopmentStatusID":"6","companyTruncated":"CDR Life \/ Boehringer Ingelheim GmbH"},{"orgOrder":0,"company":"CDR Life","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"SWITZERLAND","productType":"Other Large Molecule","year":"2024","type":"Inapplicable","leadProduct":"BI 771716","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Phase I","graph3":"CDR Life","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"CDR Life \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"CDR Life \/ Inapplicable"},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"GERMANY","productType":"Other Large Molecule","year":"2024","type":"Inapplicable","leadProduct":"BI 771716","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Phase I","graph3":"Boehringer Ingelheim GmbH","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Boehringer Ingelheim GmbH \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Boehringer Ingelheim GmbH \/ Inapplicable"},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"GERMANY","productType":"Other Large Molecule","year":"2023","type":"Inapplicable","leadProduct":"BI 771716","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Phase I","graph3":"Boehringer Ingelheim GmbH","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Boehringer Ingelheim GmbH \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Boehringer Ingelheim GmbH \/ Inapplicable"},{"orgOrder":0,"company":"ONL Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"ONL1204","moa":"Fas","graph1":"Ophthalmology","graph2":"Phase I","graph3":"ONL Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"ONL Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"ONL Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Michelle Abou-Jaoude","sponsor":"Inflammasome Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"SOM-401","moa":"Nucleoside reverse transcriptase","graph1":"Ophthalmology","graph2":"Phase I","graph3":"Michelle Abou-Jaoude","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Michelle Abou-Jaoude \/ Inflammasome Therapeutics","highestDevelopmentStatusID":"6","companyTruncated":"Michelle Abou-Jaoude \/ Inflammasome Therapeutics"},{"orgOrder":0,"company":"Ocular Therapeutix","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Axitinib","moa":"Vascular endothelial growth factor receptor","graph1":"Ophthalmology","graph2":"Phase I","graph3":"Ocular Therapeutix","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Implant","sponsorNew":"Ocular Therapeutix \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Ocular Therapeutix \/ Inapplicable"},{"orgOrder":0,"company":"Ocular Therapeutix","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Axitinib","moa":"Vascular endothelial growth factor receptor","graph1":"Ophthalmology","graph2":"Phase I","graph3":"Ocular Therapeutix","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Implant","sponsorNew":"Ocular Therapeutix \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Ocular Therapeutix \/ Inapplicable"},{"orgOrder":0,"company":"Inflammasome Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Kamuvudine-8","moa":"Nucleoside reverse transcriptase","graph1":"Ophthalmology","graph2":"Phase I","graph3":"Inflammasome Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Inflammasome Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Inflammasome Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"ONL Therapeutics","sponsor":"Bios Partners","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Series B Financing","leadProduct":"ONL1204","moa":"Fas","graph1":"Ophthalmology","graph2":"Phase I","graph3":"ONL Therapeutics","amount2":0.050000000000000003,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Ophthalmology","amount2New":0.050000000000000003,"dosageForm":"Intravitreal Injection","sponsorNew":"ONL Therapeutics \/ Bios Partners","highestDevelopmentStatusID":"6","companyTruncated":"ONL Therapeutics \/ Bios Partners"},{"orgOrder":0,"company":"Ocular Therapeutix","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Axitinib","moa":"Vascular endothelial growth factor receptor","graph1":"Ophthalmology","graph2":"Phase I","graph3":"Ocular Therapeutix","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Implant","sponsorNew":"Ocular Therapeutix \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Ocular Therapeutix \/ Inapplicable"},{"orgOrder":0,"company":"Ocular Therapeutix","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Axitinib","moa":"Vascular endothelial growth factor receptor","graph1":"Ophthalmology","graph2":"Phase I","graph3":"Ocular Therapeutix","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Implant","sponsorNew":"Ocular Therapeutix \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Ocular Therapeutix \/ Inapplicable"},{"orgOrder":0,"company":"Ocular Therapeutix","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Axitinib","moa":"Vascular endothelial growth factor receptor","graph1":"Ophthalmology","graph2":"Phase I","graph3":"Ocular Therapeutix","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Implant","sponsorNew":"Ocular Therapeutix \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Ocular Therapeutix \/ Inapplicable"},{"orgOrder":0,"company":"Ocular Therapeutix","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Axitinib","moa":"Vascular endothelial growth factor receptor","graph1":"Ophthalmology","graph2":"Phase I","graph3":"Ocular Therapeutix","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Implant","sponsorNew":"Ocular Therapeutix \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Ocular Therapeutix \/ Inapplicable"},{"orgOrder":0,"company":"Ocular Therapeutix","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Axitinib","moa":"Vascular endothelial growth factor receptor","graph1":"Ophthalmology","graph2":"Phase I","graph3":"Ocular Therapeutix","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Implant","sponsorNew":"Ocular Therapeutix \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Ocular Therapeutix \/ Inapplicable"},{"orgOrder":0,"company":"Betta Pharmaceuticals","sponsor":"EyePoint Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"CHINA","productType":"Other Small Molecule","year":"2022","type":"Licensing Agreement","leadProduct":"Vorolanib","moa":"angiogenesis inhibitors","graph1":"Ophthalmology","graph2":"Phase I","graph3":"Betta Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Betta Pharmaceuticals \/ EyePoint Pharmaceuticals","highestDevelopmentStatusID":"6","companyTruncated":"Betta Pharmaceuticals \/ EyePoint Pharmaceuticals"},{"orgOrder":0,"company":"Inflammasome Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Kamuvudine-8","moa":"Nucleoside reverse transcriptase","graph1":"Ophthalmology","graph2":"Phase I","graph3":"Inflammasome Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Inflammasome Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Inflammasome Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Ocugen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"OCU200","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Phase I","graph3":"Ocugen","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Ocugen \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Ocugen \/ Inapplicable"},{"orgOrder":0,"company":"Ocugen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Protein","year":"2024","type":"Inapplicable","leadProduct":"OCU200","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Phase I","graph3":"Ocugen","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Ocugen \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Ocugen \/ Inapplicable"},{"orgOrder":0,"company":"Ocugen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Protein","year":"2025","type":"Inapplicable","leadProduct":"OCU200","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Phase I","graph3":"Ocugen","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Ocugen \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Ocugen \/ Inapplicable"},{"orgOrder":0,"company":"Ocugen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Protein","year":"2025","type":"Inapplicable","leadProduct":"OCU200","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Phase I","graph3":"Ocugen","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Ocugen \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Ocugen \/ Inapplicable"},{"orgOrder":0,"company":"AlloVir","sponsor":"Kalaris Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Protein","year":"2025","type":"Merger","leadProduct":"TH103","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Phase I","graph3":"AlloVir","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"AlloVir \/ Kalaris Therapeutics","highestDevelopmentStatusID":"6","companyTruncated":"AlloVir \/ Kalaris Therapeutics"},{"orgOrder":0,"company":"AlloVir","sponsor":"Kalaris Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Protein","year":"2024","type":"Merger","leadProduct":"TH103","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Phase I","graph3":"AlloVir","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"AlloVir \/ Kalaris Therapeutics","highestDevelopmentStatusID":"6","companyTruncated":"AlloVir \/ Kalaris Therapeutics"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"SWITZERLAND","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"RO7303359","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Phase I","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"F. Hoffmann-La Roche \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"F. Hoffmann-La Roche \/ Inapplicable"},{"orgOrder":0,"company":"Shanghai Biomabs Pharmaceutical Co., Ltd.","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"CMAB818","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Phase I","graph3":"Shanghai Biomabs Pharmaceutical Co., Ltd.","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Shanghai Biomabs Pharmaceutical Co., Ltd. \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Shanghai Biomabs Pharmaceutical Co., Ltd. \/ Inapplicable"},{"orgOrder":0,"company":"Clover Biopharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"CHINA","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"SCB-420","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Phase I","graph3":"Clover Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Clover Biopharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Clover Biopharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"ProQR Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"NETHERLANDS","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"QR-504a","moa":"TCF4 gene expression","graph1":"Ophthalmology","graph2":"Phase I","graph3":"ProQR Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"ProQR Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"ProQR Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Shanghai General Hospital","sponsor":"4B Technologies","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"FB1001","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Phase I","graph3":"Shanghai General Hospital","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Shanghai General Hospital \/ 4B Technologies","highestDevelopmentStatusID":"6","companyTruncated":"Shanghai General Hospital \/ 4B Technologies"},{"orgOrder":0,"company":"Jiayin Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"EXG202","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Phase I","graph3":"Jiayin Biotech","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Jiayin Biotech \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Jiayin Biotech \/ Inapplicable"},{"orgOrder":0,"company":"PharmAbcine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"SOUTH KOREA","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"PMC-403","moa":"Tie2","graph1":"Ophthalmology","graph2":"Phase I","graph3":"PharmAbcine","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"PharmAbcine \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"PharmAbcine \/ Inapplicable"},{"orgOrder":0,"company":"Ocugen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"OCU200","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Phase I","graph3":"Ocugen","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Ocugen \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Ocugen \/ Inapplicable"},{"orgOrder":0,"company":"Allgenesis Biotherapeutics","sponsor":"Ora, Inc","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"TAIWAN","productType":"Peptide","year":"2022","type":"Inapplicable","leadProduct":"AG-80308","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Phase I","graph3":"Allgenesis Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Allgenesis Biotherapeutics \/ Ora, Inc","highestDevelopmentStatusID":"6","companyTruncated":"Allgenesis Biotherapeutics \/ Ora, Inc"},{"orgOrder":0,"company":"Allgenesis Biotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"TAIWAN","productType":"Peptide","year":"2023","type":"Inapplicable","leadProduct":"AG-80308","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Phase I","graph3":"Allgenesis Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Allgenesis Biotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Allgenesis Biotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Tufts Medical Center","sponsor":"Dompe Farmaceutici","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"Cenegermin","moa":"Neurotrophic tyrosine kinase receptor","graph1":"Ophthalmology","graph2":"Phase I","graph3":"Tufts Medical Center","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Tufts Medical Center \/ Dompe Farmaceutici","highestDevelopmentStatusID":"6","companyTruncated":"Tufts Medical Center \/ Dompe Farmaceutici"},{"orgOrder":0,"company":"Skye Bioscience","sponsor":"5Am Ventures","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Controlled Substance","year":"2023","type":"Financing","leadProduct":"Tetrahydrocannabinol Valine Hemisuccinate","moa":"CB1\/CB2 receptor","graph1":"Ophthalmology","graph2":"Phase I","graph3":"Skye Bioscience","amount2":0.02,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Ophthalmology","amount2New":0.02,"dosageForm":"Ophthalmic Emulsion","sponsorNew":"Skye Bioscience \/ 5Am Ventures","highestDevelopmentStatusID":"6","companyTruncated":"Skye Bioscience \/ 5Am Ventures"},{"orgOrder":0,"company":"Skye Bioscience","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Tetrahydrocannabinol Valine Hemisuccinate","moa":"CB1\/CB2 receptor","graph1":"Ophthalmology","graph2":"Phase I","graph3":"Skye Bioscience","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Emulsion","sponsorNew":"Skye Bioscience \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Skye Bioscience \/ Inapplicable"},{"orgOrder":0,"company":"Skye Bioscience","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Tetrahydrocannabinol Valine Hemisuccinate","moa":"CB1\/CB2 receptor","graph1":"Ophthalmology","graph2":"Phase I","graph3":"Skye Bioscience","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Emulsion","sponsorNew":"Skye Bioscience \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Skye Bioscience \/ Inapplicable"},{"orgOrder":0,"company":"Skye Bioscience","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Tetrahydrocannabinol Valine Hemisuccinate","moa":"CB1\/CB2 receptor","graph1":"Ophthalmology","graph2":"Phase I","graph3":"Skye Bioscience","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Emulsion","sponsorNew":"Skye Bioscience \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Skye Bioscience \/ Inapplicable"},{"orgOrder":0,"company":"PolyActiva","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"AUSTRALIA","productType":"HPAPI","year":"2023","type":"Inapplicable","leadProduct":"Latanoprost","moa":"Prostanoid FP receptor","graph1":"Ophthalmology","graph2":"Phase I","graph3":"PolyActiva","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Implant","sponsorNew":"PolyActiva \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"PolyActiva \/ Inapplicable"},{"orgOrder":0,"company":"PolyActiva","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"AUSTRALIA","productType":"HPAPI","year":"2020","type":"Inapplicable","leadProduct":"Latanoprost","moa":"Prostanoid FP receptor","graph1":"Ophthalmology","graph2":"Phase I","graph3":"PolyActiva","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Implant","sponsorNew":"PolyActiva \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"PolyActiva \/ Inapplicable"},{"orgOrder":0,"company":"PolyActiva","sponsor":"Medical Research Future Fund","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"AUSTRALIA","productType":"HPAPI","year":"2024","type":"Funding","leadProduct":"Latanoprost","moa":"Prostanoid FP receptor","graph1":"Ophthalmology","graph2":"Phase I","graph3":"PolyActiva","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Implant","sponsorNew":"PolyActiva \/ Medical Research Future Fund","highestDevelopmentStatusID":"6","companyTruncated":"PolyActiva \/ Medical Research Future Fund"},{"orgOrder":0,"company":"OliX Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"SOUTH KOREA","productType":"Oligonucleotide","year":"2023","type":"Inapplicable","leadProduct":"OLX10212","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Phase I","graph3":"OliX Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic","sponsorNew":"OliX Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"OliX Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Sylentis","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"SPAIN","productType":"Oligonucleotide","year":"2021","type":"Inapplicable","leadProduct":"SYL18001","moa":"Nrarp","graph1":"Ophthalmology","graph2":"Phase I","graph3":"Sylentis","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Sylentis \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Sylentis \/ Inapplicable"},{"orgOrder":0,"company":"Claris Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Large Molecule","year":"2024","type":"Inapplicable","leadProduct":"CSB-001","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Phase I","graph3":"Claris Bio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Claris Bio \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Claris Bio \/ Inapplicable"},{"orgOrder":0,"company":"Claris Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Large Molecule","year":"2024","type":"Inapplicable","leadProduct":"CSB-001","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Phase I","graph3":"Claris Bio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Claris Bio \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Claris Bio \/ Inapplicable"},{"orgOrder":0,"company":"Stephen J. Kim, MD","sponsor":"Allergan | National Eye Institute","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Ketorolac Trometamol","moa":"Cyclooxygenase","graph1":"Ophthalmology","graph2":"Phase I","graph3":"Stephen J. Kim, MD","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Stephen J. Kim, MD \/ Allergan | National Eye Institute","highestDevelopmentStatusID":"6","companyTruncated":"Stephen J. Kim, MD \/ Allergan | National Eye Institute"},{"orgOrder":0,"company":"Clementia Pharmaceuticals","sponsor":"Ipsen","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"CANADA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Palovarotene","moa":"Retinoic acid receptor gamma","graph1":"Ophthalmology","graph2":"Phase I","graph3":"Clementia Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Clementia Pharmaceuticals \/ Ipsen","highestDevelopmentStatusID":"6","companyTruncated":"Clementia Pharmaceuticals \/ Ipsen"},{"orgOrder":0,"company":"Kukje Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"KSR-001","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Phase I","graph3":"Kukje Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Kukje Pharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Kukje Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Eximore","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Sodium Hyaluronate","moa":"CD44","graph1":"Ophthalmology","graph2":"Phase I","graph3":"Eximore","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Eximore \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Eximore \/ Inapplicable"},{"orgOrder":0,"company":"Indonesia University","sponsor":"Dexa Medica","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Moxifloxacin","moa":"Bacterial DNA gyrase","graph1":"Ophthalmology","graph2":"Phase I","graph3":"Indonesia University","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Indonesia University \/ Dexa Medica","highestDevelopmentStatusID":"6","companyTruncated":"Indonesia University \/ Dexa Medica"},{"orgOrder":0,"company":"LENZ Therapeutics","sponsor":"Ora, Inc","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Aceclidine Hydrochloride","moa":"muscarinic receptor agonists","graph1":"Ophthalmology","graph2":"Phase I","graph3":"LENZ Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"LENZ Therapeutics \/ Ora, Inc","highestDevelopmentStatusID":"6","companyTruncated":"LENZ Therapeutics \/ Ora, Inc"},{"orgOrder":0,"company":"Ohio State University","sponsor":"University of Houston | State University of New York | Pennsylvania College of Optometry | Southern California College of Optometry at Marshall B. Ketchum University | University of California, Berkeley | Stanford University | Case Western Reserve Univers","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Atropine","moa":"Muscarinic acetylcholine receptor M3 | Muscarinic acetylcholine receptor M2 | Muscarinic acetylcholine receptor M1","graph1":"Ophthalmology","graph2":"Phase I","graph3":"Ohio State University","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Ohio State University \/ University of Houston | State University of New York | Pennsylvania College of Optometry | Southern California College of Optometry at Marshall B. Ketchum University | University of California, Berkeley | Stanford University | Case Western Reserve Univers","highestDevelopmentStatusID":"6","companyTruncated":"Ohio State University \/ University of Houston | State University of New York | Pennsylvania College of Optometry | Southern California College of Optometry at Marshall B. Ketchum University | University of California, Berkeley | Stanford University | Case Western Reserve Univers"},{"orgOrder":0,"company":"Jemincare","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"CHINA","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"JMKX003948","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Phase I","graph3":"Jemincare","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Suspension","sponsorNew":"Jemincare \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Jemincare \/ Inapplicable"},{"orgOrder":0,"company":"Nanomerics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"OC134","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Phase I","graph3":"Nanomerics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Nanomerics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Nanomerics \/ Inapplicable"},{"orgOrder":0,"company":"Nanomerics","sponsor":"Quotient Sciences","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"OC134","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Phase I","graph3":"Nanomerics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Nanomerics \/ Quotient Sciences","highestDevelopmentStatusID":"6","companyTruncated":"Nanomerics \/ Quotient Sciences"},{"orgOrder":0,"company":"Nanomerics","sponsor":"Quotient Sciences","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"OC134","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Phase I","graph3":"Nanomerics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Nanomerics \/ Quotient Sciences","highestDevelopmentStatusID":"6","companyTruncated":"Nanomerics \/ Quotient Sciences"},{"orgOrder":0,"company":"Quotient Sciences","sponsor":"Nanomerics","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"OC134","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Phase I","graph3":"Quotient Sciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Quotient Sciences \/ Nanomerics","highestDevelopmentStatusID":"6","companyTruncated":"Quotient Sciences \/ Nanomerics"},{"orgOrder":0,"company":"DelSiTech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"FINLAND","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"DST-2105","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Phase I","graph3":"DelSiTech","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"DelSiTech \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"DelSiTech \/ Inapplicable"},{"orgOrder":0,"company":"Active Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"SWEDEN","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Laquinimod","moa":"immunomodulators","graph1":"Ophthalmology","graph2":"Phase I","graph3":"Active Biotech","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Active Biotech \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Active Biotech \/ Inapplicable"},{"orgOrder":0,"company":"Famar","sponsor":"Active Biotech","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"GREECE","productType":"Other Small Molecule","year":"2021","type":"Agreement","leadProduct":"Laquinimod","moa":"immunomodulators","graph1":"Ophthalmology","graph2":"Phase I","graph3":"Famar","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Famar \/ Active Biotech","highestDevelopmentStatusID":"6","companyTruncated":"Famar \/ Active Biotech"},{"orgOrder":0,"company":"Active Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"SWEDEN","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Laquinimod","moa":"immunomodulators","graph1":"Ophthalmology","graph2":"Phase I","graph3":"Active Biotech","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Active Biotech \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Active Biotech \/ Inapplicable"},{"orgOrder":0,"company":"Xequel Bio","sponsor":"US Department of Defense","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Peptide","year":"2021","type":"Inapplicable","leadProduct":"Inexin","moa":"CX43","graph1":"Ophthalmology","graph2":"Phase I","graph3":"Xequel Bio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Xequel Bio \/ US Department of Defense","highestDevelopmentStatusID":"6","companyTruncated":"Xequel Bio \/ US Department of Defense"},{"orgOrder":0,"company":"Xequel Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Peptide","year":"2022","type":"Inapplicable","leadProduct":"iNexin","moa":"CX43","graph1":"Ophthalmology","graph2":"Phase I","graph3":"Xequel Bio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Xequel Bio \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Xequel Bio \/ Inapplicable"},{"orgOrder":0,"company":"Xequel Bio","sponsor":"Societal CDMO","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Peptide","year":"2023","type":"Agreement","leadProduct":"iNexin","moa":"CX43","graph1":"Ophthalmology","graph2":"Phase I","graph3":"Xequel Bio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Xequel Bio \/ Societal CDMO","highestDevelopmentStatusID":"6","companyTruncated":"Xequel Bio \/ Societal CDMO"},{"orgOrder":0,"company":"OphRx","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Cyclosporine","moa":"Cyclophilin A","graph1":"Ophthalmology","graph2":"Phase I","graph3":"OphRx","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic","sponsorNew":"OphRx \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"OphRx \/ Inapplicable"},{"orgOrder":0,"company":"Trefoil Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"TTHX1114","moa":"FGF1","graph1":"Ophthalmology","graph2":"Phase I","graph3":"Trefoil Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Trefoil Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Trefoil Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Sunhawk Vision Biotech, Inc.","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"SHJ002","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Phase I","graph3":"Sunhawk Vision Biotech, Inc.","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic","sponsorNew":"Sunhawk Vision Biotech, Inc. \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Sunhawk Vision Biotech, Inc. \/ Inapplicable"},{"orgOrder":0,"company":"Shanghai Medinno Pharmaceutical Technology Co., Ltd.","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"MDI-1228 Mesylate","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Phase I","graph3":"Shanghai Medinno Pharmaceutical Technology Co., Ltd.","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Shanghai Medinno Pharmaceutical Technology Co., Ltd. \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Shanghai Medinno Pharmaceutical Technology Co., Ltd. \/ Inapplicable"},{"orgOrder":0,"company":"CAREGEN CO. LTD.","sponsor":"CBCC Global","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"SOUTH KOREA","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"CG-P5 Peptide","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Phase I","graph3":"CAREGEN CO. LTD.","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"CAREGEN CO. LTD. \/ CBCC Global","highestDevelopmentStatusID":"6","companyTruncated":"CAREGEN CO. LTD. \/ CBCC Global"},{"orgOrder":0,"company":"Huons CO., LTD","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"SOUTH KOREA","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"NCP112","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Phase I","graph3":"Huons CO., LTD","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Huons CO., LTD \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Huons CO., LTD \/ Inapplicable"},{"orgOrder":0,"company":"Skye Bioscience","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Controlled Substance","year":"2021","type":"Inapplicable","leadProduct":"Netarsudil","moa":"||CB1\/CB2 receptor","graph1":"Ophthalmology","graph2":"Phase I","graph3":"Skye Bioscience","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Emulsion","sponsorNew":"Skye Bioscience \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Skye Bioscience \/ Inapplicable"},{"orgOrder":0,"company":"OliX Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"SOUTH KOREA","productType":"Oligonucleotide","year":"2022","type":"Inapplicable","leadProduct":"OLX10212","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Phase I","graph3":"OliX Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic","sponsorNew":"OliX Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"OliX Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Nanomerics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"OC134","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Phase I","graph3":"Nanomerics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Nanomerics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Nanomerics \/ Inapplicable"},{"orgOrder":0,"company":"Skye Bioscience","sponsor":"CMAX","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Controlled Substance","year":"2022","type":"Agreement","leadProduct":"Tetrahydrocannabinol Valine Hemisuccinate","moa":"CB1\/CB2 receptor","graph1":"Ophthalmology","graph2":"Phase I","graph3":"Skye Bioscience","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Emulsion","sponsorNew":"Skye Bioscience \/ CMAX","highestDevelopmentStatusID":"6","companyTruncated":"Skye Bioscience \/ CMAX"},{"orgOrder":0,"company":"Skye Bioscience","sponsor":"Emerald Health Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Controlled Substance","year":"2022","type":"Agreement","leadProduct":"Tetrahydrocannabinol Valine Hemisuccinate","moa":"CB1\/CB2 receptor","graph1":"Ophthalmology","graph2":"Phase I","graph3":"Skye Bioscience","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Emulsion","sponsorNew":"Skye Bioscience \/ Emerald Health Therapeutics","highestDevelopmentStatusID":"6","companyTruncated":"Skye Bioscience \/ Emerald Health Therapeutics"},{"orgOrder":0,"company":"Skye Bioscience","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Controlled Substance","year":"2021","type":"Inapplicable","leadProduct":"Netarsudil","moa":"||CB1\/CB2 receptor","graph1":"Ophthalmology","graph2":"Phase I","graph3":"Skye Bioscience","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Emulsion","sponsorNew":"Skye Bioscience \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Skye Bioscience \/ Inapplicable"},{"orgOrder":0,"company":"Skye Bioscience","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Controlled Substance","year":"2021","type":"Inapplicable","leadProduct":"Netarsudil","moa":"||CB1\/CB2 receptor","graph1":"Ophthalmology","graph2":"Phase I","graph3":"Skye Bioscience","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Emulsion","sponsorNew":"Skye Bioscience \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Skye Bioscience \/ Inapplicable"},{"orgOrder":0,"company":"Skye Bioscience","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Tetrahydrocannabinol Valine Hemisuccinate","moa":"CB1\/CB2 receptor","graph1":"Ophthalmology","graph2":"Phase I","graph3":"Skye Bioscience","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Emulsion","sponsorNew":"Skye Bioscience \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Skye Bioscience \/ Inapplicable"},{"orgOrder":0,"company":"Skye Bioscience","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Tetrahydrocannabinol Valine Hemisuccinate","moa":"CB1\/CB2 receptor","graph1":"Ophthalmology","graph2":"Phase I","graph3":"Skye Bioscience","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Emulsion","sponsorNew":"Skye Bioscience \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Skye Bioscience \/ Inapplicable"},{"orgOrder":0,"company":"Skye Bioscience","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Tetrahydrocannabinol Valine Hemisuccinate","moa":"CB1\/CB2 receptor","graph1":"Ophthalmology","graph2":"Phase I","graph3":"Skye Bioscience","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Emulsion","sponsorNew":"Skye Bioscience \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Skye Bioscience \/ Inapplicable"},{"orgOrder":0,"company":"Michelle Abou-Jaoude","sponsor":"Inflammasome Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Kamuvudine-9","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Phase I","graph3":"Michelle Abou-Jaoude","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Michelle Abou-Jaoude \/ Inflammasome Therapeutics","highestDevelopmentStatusID":"6","companyTruncated":"Michelle Abou-Jaoude \/ Inflammasome Therapeutics"},{"orgOrder":0,"company":"Undisclosed","sponsor":"Vantage Biosciences","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"","productType":"Other Small Molecule","year":"2023","type":"Acquisition","leadProduct":"VX-01","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Phase I","graph3":"Undisclosed","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Undisclosed \/ Vantage Biosciences","highestDevelopmentStatusID":"6","companyTruncated":"Undisclosed \/ Vantage Biosciences"},{"orgOrder":0,"company":"Cognition Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Zervimesine","moa":"TMEM97","graph1":"Ophthalmology","graph2":"Phase I","graph3":"Cognition Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Cognition Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Cognition Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Cognition Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Zervimesine","moa":"TMEM97","graph1":"Ophthalmology","graph2":"Phase I","graph3":"Cognition Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Cognition Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Cognition Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Curacle","sponsor":"Laboratoires Thea","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"SOUTH KOREA","productType":"Other Small Molecule","year":"2021","type":"Collaboration","leadProduct":"CU06","moa":"Endothelial dysfunction","graph1":"Ophthalmology","graph2":"Phase I","graph3":"Curacle","amount2":2.1600000000000001,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Ophthalmology","amount2New":2.1600000000000001,"dosageForm":"Oral Capsule","sponsorNew":"Curacle \/ Laboratoires Thea","highestDevelopmentStatusID":"6","companyTruncated":"Curacle \/ Laboratoires Thea"},{"orgOrder":0,"company":"Drug Farm","sponsor":"National Institute of Allergy and Infectious Diseases","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"CHINA","productType":"Other Small Molecule","year":"2024","type":"Agreement","leadProduct":"8-Bromo-pet-cyclic gmps","moa":"ALPK1","graph1":"Ophthalmology","graph2":"Phase I","graph3":"Drug Farm","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Drug Farm \/ National Institute of Allergy and Infectious Diseases","highestDevelopmentStatusID":"6","companyTruncated":"Drug Farm \/ National Institute of Allergy and Infectious Diseases"},{"orgOrder":0,"company":"Drug Farm","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"CHINA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"8-Bromo-pet-cyclic gmps","moa":"ALPK1","graph1":"Ophthalmology","graph2":"Phase I","graph3":"Drug Farm","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Drug Farm \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Drug Farm \/ Inapplicable"},{"orgOrder":0,"company":"Drug Farm","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"CHINA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"8-Bromo-pet-cyclic gmps","moa":"ALPK1","graph1":"Ophthalmology","graph2":"Phase I","graph3":"Drug Farm","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Drug Farm \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Drug Farm \/ Inapplicable"},{"orgOrder":0,"company":"Galimedix Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"GAL-101","moa":"APP","graph1":"Ophthalmology","graph2":"Phase I","graph3":"Galimedix Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Galimedix Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Galimedix Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"AnewPharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"Vorolanib","moa":"VEGF receptor\/PDGFR","graph1":"Ophthalmology","graph2":"Phase I","graph3":"AnewPharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Oral","sponsorNew":"AnewPharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"AnewPharma \/ Inapplicable"},{"orgOrder":0,"company":"Drug Farm","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"CHINA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"8-Bromo-pet-cyclic gmps","moa":"ALPK1","graph1":"Ophthalmology","graph2":"Phase I","graph3":"Drug Farm","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Drug Farm \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Drug Farm \/ Inapplicable"},{"orgOrder":0,"company":"AiViva Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Lenvatinib","moa":"Vascular endothelial growth factor receptor","graph1":"Ophthalmology","graph2":"Phase I","graph3":"AiViva Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Periocular Injection","sponsorNew":"AiViva Biopharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"AiViva Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"Exegenesis Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"EXG102-031","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Phase I","graph3":"Exegenesis Bio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Subretinal Injection","sponsorNew":"Exegenesis Bio \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Exegenesis Bio \/ Inapplicable"},{"orgOrder":0,"company":"Li Xiaorong","sponsor":"Shanghai Refreshgene Technology Co., Ltd.","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"RRG001","moa":"VEGFR","graph1":"Ophthalmology","graph2":"Phase I","graph3":"Li Xiaorong","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Subretinal Injection","sponsorNew":"Li Xiaorong \/ Shanghai Refreshgene Technology Co., Ltd.","highestDevelopmentStatusID":"6","companyTruncated":"Li Xiaorong \/ Shanghai Refreshgene Technology Co., Ltd."},{"orgOrder":0,"company":"HuidaGene Therapeutics","sponsor":"Tianjin Medical University Eye Hospital | Gene Therapy Research Center, Shariati Hospital, Tehran University of Medical Sciences, Iran","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"CHINA","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"HG202","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Phase I","graph3":"HuidaGene Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Subretinal Injection","sponsorNew":"HuidaGene Therapeutics \/ Tianjin Medical University Eye Hospital | Gene Therapy Research Center, Shariati Hospital, Tehran University of Medical Sciences, Iran","highestDevelopmentStatusID":"6","companyTruncated":"HuidaGene Therapeutics \/ Tianjin Medical University Eye Hospital | Gene Therapy Research Center, Shariati Hospital, Tehran University of Medical Sciences, Iran"},{"orgOrder":0,"company":"HuidaGene Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"CHINA","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"HG202","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Phase I","graph3":"HuidaGene Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Subretinal Injection","sponsorNew":"HuidaGene Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"HuidaGene Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Therini Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"CANADA","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"THN391","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Phase I","graph3":"Therini Bio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Therini Bio \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Therini Bio \/ Inapplicable"},{"orgOrder":0,"company":"Therini Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"CANADA","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"THN391","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Phase I","graph3":"Therini Bio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Therini Bio \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Therini Bio \/ Inapplicable"},{"orgOrder":0,"company":"Emmecell","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"EO2002","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Phase I","graph3":"Emmecell","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Strip","sponsorNew":"Emmecell \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Emmecell \/ Inapplicable"},{"orgOrder":0,"company":"PolyActiva","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"AUSTRALIA","productType":"Antibiotic","year":"2020","type":"Inapplicable","leadProduct":"Levofloxacin","moa":"Topoisomerase IV | DNA gyrase","graph1":"Ophthalmology","graph2":"Phase I","graph3":"PolyActiva","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Implant","sponsorNew":"PolyActiva \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"PolyActiva \/ Inapplicable"},{"orgOrder":0,"company":"PolyActiva","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"AUSTRALIA","productType":"Antibiotic","year":"2022","type":"Inapplicable","leadProduct":"Levofloxacin","moa":"Topoisomerase IV | DNA gyrase","graph1":"Ophthalmology","graph2":"Phase I","graph3":"PolyActiva","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Implant","sponsorNew":"PolyActiva \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"PolyActiva \/ Inapplicable"},{"orgOrder":0,"company":"AffaMed Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"AM712","moa":"VEGF receptor","graph1":"Ophthalmology","graph2":"Phase I","graph3":"AffaMed Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AffaMed Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"AffaMed Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Innovent Biologics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"CHINA","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"IBI324","moa":"VEGF-A\/Ang-2 receptor","graph1":"Ophthalmology","graph2":"Phase I","graph3":"Innovent Biologics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Innovent Biologics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Innovent Biologics \/ Inapplicable"},{"orgOrder":0,"company":"Allakos","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Lirentelimab","moa":"Sialic acid-binding Ig-like lectin 8","graph1":"Ophthalmology","graph2":"Phase I","graph3":"Allakos","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Allakos \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Allakos \/ Inapplicable"},{"orgOrder":0,"company":"AffaMed Therapeutics","sponsor":"AskGene Pharma Inc","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"ASKG712","moa":"VEGF receptor","graph1":"Ophthalmology","graph2":"Phase I","graph3":"AffaMed Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AffaMed Therapeutics \/ AskGene Pharma Inc","highestDevelopmentStatusID":"6","companyTruncated":"AffaMed Therapeutics \/ AskGene Pharma Inc"},{"orgOrder":0,"company":"PS Therapy","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Phase I","graph3":"PS Therapy","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"PS Therapy \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"PS Therapy \/ Inapplicable"},{"orgOrder":0,"company":"PYC Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"AUSTRALIA","productType":"Oligonucleotide","year":"2023","type":"Inapplicable","leadProduct":"VP-001","moa":"PRPF31","graph1":"Ophthalmology","graph2":"Phase I","graph3":"PYC Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"PYC Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"PYC Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"GSK","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"GSK2798745","moa":"Transient receptor potential cation channel subfamily V member 4","graph1":"Ophthalmology","graph2":"Phase I","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"GSK \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"GSK \/ Inapplicable"},{"orgOrder":0,"company":"Active Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"SWEDEN","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Laquinimod","moa":"immunomodulators","graph1":"Ophthalmology","graph2":"Phase I","graph3":"Active Biotech","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Active Biotech \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Active Biotech \/ Inapplicable"},{"orgOrder":0,"company":"Egymedicalpedia","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Mitomycin","moa":"DNA","graph1":"Ophthalmology","graph2":"Phase I","graph3":"Egymedicalpedia","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Egymedicalpedia \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Egymedicalpedia \/ Inapplicable"},{"orgOrder":0,"company":"RBP4","sponsor":"Belite Bio","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Tinlarebant","moa":"RBP4","graph1":"Ophthalmology","graph2":"Phase I","graph3":"RBP4","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"RBP4 \/ Belite Bio","highestDevelopmentStatusID":"6","companyTruncated":"RBP4 \/ Belite Bio"},{"orgOrder":0,"company":"Ocular Therapeutix","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"OTX-TKI","moa":"VEGFR","graph1":"Ophthalmology","graph2":"Phase I","graph3":"Ocular Therapeutix","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Ocular Therapeutix \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Ocular Therapeutix \/ Inapplicable"},{"orgOrder":0,"company":"Oyster Point Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Varenicline Tartrate","moa":"Neuronal acetylcholine receptor; alpha4\/beta2","graph1":"Ophthalmology","graph2":"Phase I","graph3":"Oyster Point Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Oyster Point Pharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Oyster Point Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Aclaris Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Zunsemetinib","moa":"||MAPKAPK2","graph1":"Ophthalmology","graph2":"Phase I","graph3":"Aclaris Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Aclaris Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Aclaris Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"AiViva Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Lenvatinib","moa":"Vascular endothelial growth factor receptor","graph1":"Ophthalmology","graph2":"Phase I","graph3":"AiViva Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AiViva Biopharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"AiViva Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"AiViva Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Lenvatinib","moa":"Vascular endothelial growth factor receptor","graph1":"Ophthalmology","graph2":"Phase I","graph3":"AiViva Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AiViva Biopharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"AiViva Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"Ocular Therapeutix","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Peptide","year":"2020","type":"Inapplicable","leadProduct":"OTX-TIC","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Phase I","graph3":"Ocular Therapeutix","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Ocular Therapeutix \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Ocular Therapeutix \/ Inapplicable"},{"orgOrder":0,"company":"Daewoong Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"SOUTH KOREA","productType":"Peptide","year":"2022","type":"Inapplicable","leadProduct":"Recombinant Human Epidermal Growth Factor","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Phase I","graph3":"Daewoong Bio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Daewoong Bio \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Daewoong Bio \/ Inapplicable"},{"orgOrder":0,"company":"Chengdu Kanghong Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Conbercept","moa":"Placenta growth factor | Vascular endothelial growth factor A | Vascular endothelial growth factor B | Vascular endothelial growth factor C","graph1":"Ophthalmology","graph2":"Phase I","graph3":"Chengdu Kanghong Biotech","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Chengdu Kanghong Biotech \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Chengdu Kanghong Biotech \/ Inapplicable"},{"orgOrder":0,"company":"Exegenesis Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Protein","year":"2025","type":"Inapplicable","leadProduct":"Aflibercept","moa":"Vascular endothelial growth factor A | Placenta growth factor","graph1":"Ophthalmology","graph2":"Phase I","graph3":"Exegenesis Bio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Exegenesis Bio \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Exegenesis Bio \/ Inapplicable"},{"orgOrder":0,"company":"SipNose","sponsor":"Noveome Biotherapeutics","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"ISRAEL","productType":"Protein","year":"2021","type":"Licensing Agreement","leadProduct":"ST266","moa":"AChE","graph1":"Ophthalmology","graph2":"Phase I","graph3":"SipNose","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Nasal","sponsorNew":"SipNose \/ Noveome Biotherapeutics","highestDevelopmentStatusID":"6","companyTruncated":"SipNose \/ Noveome Biotherapeutics"},{"orgOrder":0,"company":"INVO Bioscience","sponsor":"Naya Biosciences","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Merger","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Phase I","graph3":"INVO Bioscience","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"INVO Bioscience \/ Naya Biosciences","highestDevelopmentStatusID":"6","companyTruncated":"INVO Bioscience \/ Naya Biosciences"},{"orgOrder":0,"company":"INVO Bioscience","sponsor":"Naya Biosciences","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Merger","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Phase I","graph3":"INVO Bioscience","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"INVO Bioscience \/ Naya Biosciences","highestDevelopmentStatusID":"6","companyTruncated":"INVO Bioscience \/ Naya Biosciences"},{"orgOrder":0,"company":"Sunshine Guojian Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"CHINA","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"Drug 601","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Phase I","graph3":"Sunshine Guojian Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Sunshine Guojian Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Sunshine Guojian Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Guangzhou HuiBoRui Biological Pharmaceutical Technology Co. Ltd","sponsor":"Parexel","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"KDR2-2","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Phase I","graph3":"Guangzhou HuiBoRui Biological Pharmaceutical Technology Co. Ltd","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Guangzhou HuiBoRui Biological Pharmaceutical Technology Co. Ltd \/ Parexel","highestDevelopmentStatusID":"6","companyTruncated":"Guangzhou HuiBoRui Biological Pharmaceutical Technology Co. Ltd \/ Parexel"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"SWITZERLAND","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"MHU650","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Phase I","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Powder for Solution","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Inapplicable"},{"orgOrder":0,"company":"CliPS","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"LSCD101","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Phase I","graph3":"CliPS","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Sheet","sponsorNew":"CliPS \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"CliPS \/ Inapplicable"},{"orgOrder":0,"company":"Sylentis","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"SPAIN","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"SYL18001 Sodium","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Phase I","graph3":"Sylentis","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sylentis \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Sylentis \/ Inapplicable"},{"orgOrder":0,"company":"Shanghai BDgene Co., Ltd.","sponsor":"Gene Therapy Research Center, Shariati Hospital, Tehran University of Medical Sciences, Iran","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"BD311","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Phase I","graph3":"Shanghai BDgene Co., Ltd.","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Shanghai BDgene Co., Ltd. \/ Gene Therapy Research Center, Shariati Hospital, Tehran University of Medical Sciences, Iran","highestDevelopmentStatusID":"6","companyTruncated":"Shanghai BDgene Co., Ltd. \/ Gene Therapy Research Center, Shariati Hospital, Tehran University of Medical Sciences, Iran"},{"orgOrder":0,"company":"Chong Kun Dang Pharm","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"SOUTH KOREA","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"D565","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Phase I","graph3":"Chong Kun Dang Pharm","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Chong Kun Dang Pharm \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Chong Kun Dang Pharm \/ Inapplicable"},{"orgOrder":0,"company":"Aurion Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"HCEC-1","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Phase I","graph3":"Aurion Biotech","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Aurion Biotech \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Aurion Biotech \/ Inapplicable"},{"orgOrder":0,"company":"Ocugen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"OCU-10-C-110","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Phase I","graph3":"Ocugen","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Ocugen \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Ocugen \/ Inapplicable"},{"orgOrder":0,"company":"Peregrine Ophthalmic","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"POLAT-001","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Phase I","graph3":"Peregrine Ophthalmic","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Peregrine Ophthalmic \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Peregrine Ophthalmic \/ Inapplicable"},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"GERMANY","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"BI771716","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Phase I","graph3":"Boehringer Ingelheim GmbH","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Boehringer Ingelheim GmbH \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Boehringer Ingelheim GmbH \/ Inapplicable"},{"orgOrder":0,"company":"InnoVec Biotherapeutics","sponsor":"NeoVec Biotherapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"IVB103","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Phase I","graph3":"InnoVec Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"InnoVec Biotherapeutics \/ NeoVec Biotherapeutics","highestDevelopmentStatusID":"6","companyTruncated":"InnoVec Biotherapeutics \/ NeoVec Biotherapeutics"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"SWITZERLAND","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"RO7200220","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Phase I","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"F. Hoffmann-La Roche \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"F. Hoffmann-La Roche \/ Inapplicable"},{"orgOrder":0,"company":"Novus Vision LLC","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"NV701","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Phase I","graph3":"Novus Vision LLC","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novus Vision LLC \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Novus Vision LLC \/ Inapplicable"},{"orgOrder":0,"company":"Genentech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"RO7497372","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Phase I","graph3":"Genentech","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Genentech \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Genentech \/ Inapplicable"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"SWITZERLAND","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"RO7669330","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Phase I","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"F. Hoffmann-La Roche \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"F. Hoffmann-La Roche \/ Inapplicable"},{"orgOrder":0,"company":"PolyActiva","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"AUSTRALIA","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"PA5436","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Phase I","graph3":"PolyActiva","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Implant","sponsorNew":"PolyActiva \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"PolyActiva \/ Inapplicable"},{"orgOrder":0,"company":"SCAI Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"SOUTH KOREA","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"SCAI-005","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Phase I","graph3":"SCAI Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"SCAI Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"SCAI Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Emmecell","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"EO2002","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Phase I","graph3":"Emmecell","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Strip","sponsorNew":"Emmecell \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Emmecell \/ Inapplicable"},{"orgOrder":0,"company":"EyeD Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"BELGIUM","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Timolol Maleate","moa":"Beta-2 adrenergic receptor | Beta-1 adrenergic receptor","graph1":"Ophthalmology","graph2":"Phase I","graph3":"EyeD Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"EyeD Pharma \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"EyeD Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Eyevensys","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"GERMANY","productType":"Cell and Gene therapy","year":"2025","type":"Inapplicable","leadProduct":"PST-611","moa":"Transferrin","graph1":"Ophthalmology","graph2":"Phase I","graph3":"Eyevensys","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Eyevensys \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Eyevensys \/ Undisclosed"},{"orgOrder":0,"company":"FELIQS","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"JAPAN","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"FLQ-101","moa":"ADRA2","graph1":"Ophthalmology","graph2":"Phase I","graph3":"FELIQS","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"FELIQS \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"FELIQS \/ Undisclosed"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"ABBV-319","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Phase I","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"AbbVie Inc \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"AbbVie Inc \/ Undisclosed"},{"orgOrder":0,"company":"Qilu Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"CHINA","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Lifitegrast","moa":"Integrin alpha-L\/beta-2 (LFA-1)","graph1":"Ophthalmology","graph2":"Phase I","graph3":"Qilu Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Qilu Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Qilu Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Shanghai General Hospital","sponsor":"Innostellar Biotherapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"","productType":"Cell and Gene therapy","year":"2025","type":"Inapplicable","leadProduct":"LX111","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Phase I","graph3":"Shanghai General Hospital","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Shanghai General Hospital \/ Innostellar Biotherapeutics","highestDevelopmentStatusID":"6","companyTruncated":"Shanghai General Hospital \/ Innostellar Biotherapeutics"},{"orgOrder":0,"company":"Bausch & Lomb Incorporated","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"CANADA","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"BL1332","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Phase I","graph3":"Bausch & Lomb Incorporated","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Bausch & Lomb Incorporated \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Bausch & Lomb Incorporated \/ Undisclosed"},{"orgOrder":0,"company":"Shanghai General Hospital","sponsor":"Innostellar Biotherapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"","productType":"Cell and Gene therapy","year":"2025","type":"Inapplicable","leadProduct":"LX107","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Phase I","graph3":"Shanghai General Hospital","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Shanghai General Hospital \/ Innostellar Biotherapeutics","highestDevelopmentStatusID":"6","companyTruncated":"Shanghai General Hospital \/ Innostellar Biotherapeutics"},{"orgOrder":0,"company":"FELIQS","sponsor":"Beyond Next Ventures","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"JAPAN","productType":"Other Small Molecule","year":"2025","type":"Series A Financing","leadProduct":"FLQ-101","moa":"Adrenergic-alpha-2 receptor","graph1":"Ophthalmology","graph2":"Phase I","graph3":"FELIQS","amount2":0.01,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Ophthalmology","amount2New":0.01,"dosageForm":"Undisclosed","sponsorNew":"FELIQS \/ Beyond Next Ventures","highestDevelopmentStatusID":"6","companyTruncated":"FELIQS \/ Beyond Next Ventures"},{"orgOrder":0,"company":"Breye Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Danegaptide","moa":"GJs","graph1":"Ophthalmology","graph2":"Phase I","graph3":"Breye Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Breye Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Breye Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Raytone Biotech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"CHINA","productType":"Antibiotic","year":"2025","type":"Inapplicable","leadProduct":"Tacrolimus","moa":"FK506-binding protein 1A","graph1":"Ophthalmology","graph2":"Phase I","graph3":"Raytone Biotech","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Insert","sponsorNew":"Raytone Biotech \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Raytone Biotech \/ Undisclosed"}]
Find Ophthalmology Drugs in Phase I Clinical Development
Filters
×
FILTER:
Company Name
Year
DEALS // DEV.
Country
Sponsor
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Reset All
FAMAR CDMO- From early development to commercial manufacturing.
